Abstract
Objective To determine the efficacy of statin treatment on risk of coronary heart disease in patients with familial hypercholesterolaemia. Design Cohort study with a mean follow- up of 8.5 years. Setting 27 outpatient lipid clinics. Subjects 2146 patients with familial hypercholesterolaemia without prevalent coronary heart disease before 1 January 1990. Main outcome measures Risk of coronary heart disease in treated and "untreated" ( delay in starting statin treatment) patients compared with a Cox regression model in which statin use was a time dependent variable. Results In January 1990, 413 ( 21%) of the patients had started statin treatment, and during follow- up another 1294 patients ( 66%) started after a mean delay of 4.3 years. Most patients received simvastatin ( n= 1167, 33 mg daily) or atorvastatin ( n= 211, 49 mg daily). We observed an overall risk reduction of 76% ( hazard ratio 0.24 ( 95% confidence interval 0.18 to 0.30), P <0.001). In fact, the risk of myocardial infarction in these statin treated patients was not significantly greater than that in an age- matched sample from the general population ( hazard ration 1.44 ( 0.80 to 2.60), P= 0.23). Conclusion Lower statin doses than those currently advised reduced the risk of coronary heart disease to a greater extent than anticipated in patients with familial hypercholesterolaemia. With statin treatment, such patients no longer have a risk of myocardial infarction significantly different from that of the general population
| Original language | English |
|---|---|
| Pages (from-to) | a2423 |
| Journal | BMJ (Clinical research ed.) |
| Volume | 337 |
| DOIs | |
| Publication status | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Efficacy of statins in familial hypercholesterolaemia: a long term cohort study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver